Richard Gaynor, M.D.
Richard Gaynor, M.D., joined our Board in 2021 and serves as Chair of the Research and Development Committee.
Dr. Gaynor is an experienced oncologist who brings to our Board deep expertise in research and development and significant experience as a senior business executive in the biopharmaceutical industry.
Dr. Gaynor is the President and Chief of Research and Development at BioNTech US (formerly Neon Therapeutics, Inc.), after serving in this role at Neon Therapeutics beginning in 2016. Previously, Dr. Gaynor spent 15 years in various senior clinical development and medical affairs roles at Eli Lilly and Company from 2002 to 2016, including as Senior Vice President of Clinical Development and Medical Affairs. Previously, he served as a Professor at the UCLA School of Medicine for nine years and on the faculty at the University of Texas Southwestern Medical School for eleven years, including as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center.
In addition to serving on our Board, he has also served on other public company boards, including Alkermes plc (Nasdaq) since 2019.
Dr. Gaynor is the author of nearly 150 publications and participates on numerous advisory boards and committees, including currently serving as a Director for the Damon Runyon Cancer Research Foundation and on committees for the American Association of Cancer Research and other cancer organizations.
Dr. Gaynor received an M.D. from the University of Texas Southwestern Medical School, where he served a residency in internal medicine. He completed fellowship training in hematology-oncology at the UCLA School of Medicine.